Middle income vs Tajikistan: Immunization, Hib3
Middle income
77.1%
in 2024
Tajikistan
97.0%
in 2024
Middle income rank
26th
Tajikistan rank
29th
Immunization, Hib3 over time
- Middle income
- Tajikistan
How they compare
Tajikistan currently reports 97.0% against 77.1% in Middle income, a difference of 19.9%.
That makes Tajikistan's figure about 1.3 times Middle income's.
Across all 17 years both countries report, Tajikistan has been ahead every year.
Middle income ranks 26th and Tajikistan ranks 29th of 43 groups.
Tajikistan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Middle income | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 23.3% | 69.5% | 46.2% | Tajikistan |
| 2010s | 52.3% | 95.9% | 43.6% | Tajikistan |
| 2020s | 73.4% | 96.8% | 23.4% | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Middle income or Tajikistan?
- Tajikistan, at 97.0% against 77.1% in Middle income as of 2024.
- What is the difference in immunization, hib3 between Middle income and Tajikistan?
- 19.9%, with Tajikistan ahead.
- How many years of comparable data are there for Middle income and Tajikistan?
- 17 years are reported by both, from 2008 to 2024.
- How do Middle income and Tajikistan rank globally for immunization, hib3?
- Middle income ranks 26th and Tajikistan ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.